While depletion of SLF2 did not affect the sensitivity to SUMOi in non‐cancer cell lines (Appendix Fig S10), we could validate the synthetic lethality driven by SLF2 loss in DLBCL in OCI‐Ly19 SLF2KO lymphoma cells (Appendix Fig S11A and B, Dataset EV1). Here, SLF2 is linked to cancer.